23rd Annual Arthur H. Briggs Lectureship
Thursday, October 27th, 2016 @ 4:00PM
Medical Bldg - Lecture Hall Room 309L


Dr. Arthur BriggsDr. Arthur H. Briggs (pictured left) served as Chair of the Department of Pharmacology at UTHSCSA from 1968 - 1993, during which time he studied the actions of drugs on the cardiovascular system, hypertension, and drugs of abuse. His laboratory published the first papers on the central role of calcium in vascular smooth muscle contraction and the interrelationships between sodium and potassium ions and drugs. These studies led to important advances in the understanding of calcium in smooth muscle function. Since his retirement in 1993, an annual lectureship has been held in his honor.

This year's guest lecturer, Bruce A. Littlefield, Ph.D. (below), serves as Distinguished Scientist and Head of Translational Medicine in the Global Oncology Medical Affairs division of Eisai, a global pharmaceutical company headquartered in Tokyo. Since joining Eisai in 1990, Dr. Littlefield has overseen numerous natural product-based oncology drug discovery programs. One such program, initiated at Eisai by Dr. Littlefield in 1992 together with Professor Yoshito Kishi of Harvard, was based on the marine sponge natural product halichondrin B. This program led to development of eribulin (Halaven®), currently approved in the U.S. and 59 other countries for treatment of certain patients with advanced breast cancer, with a recent additional approval for advanced liposarcoma in the U.S. Dr. Littlefield has published widely in the cancer research area, holds numerous drug development-related patents, and is a frequent lecturer at universities and scientific conferences in the US and abroad. In addition to working at Eisai, Dr. Littlefield has held faculty positions at both Yale and Harvard Medical Schools, most recently 2009-2011, when he temporarily joined Harvard to oversee scientific development of a new natural products research program, before returning to Eisai in his current capacity in 2011.

The title of his talk is: 'Discovery and Development of Eribulin (Halaven®), a Macrocyclic Ketone Analog of Halichondrin B, for Treatment of Advanced Breast Cancer and Liposarcoma'


Dr. Bruce Littlefield
23rd Annual Arthur H. Briggs Guest Lecturer Bruce A. Littlefield, Ph.D.


Dr. Peter Senter, 2015
Dr. Husseini K. Manji, 2014
Dr. P. Jeffrey Conn, 2013
Dr. Michel Bouvier, 2012
Dr. James H. Woods, 2011
Dr. Floyd E. Bloom, 2010
Dr. Mark Von Zastrow, 2009
Dr. Tomas Hökfelt, 2008
Dr. Marc Caron, 2007
Dr. Terry Kenakin, 2006
Dr. G. Stanley McKnight, 2005
Dr. Brian Kobilka, 2004
Dr. David J. Triggle, 2003
Professor James Black, 2002
Dr. Raymond J. Dingledine, 2001
Dr. William A. Catterall, 2000
Dr. Henry Bourne, 1999
Dr. Ira Black, 1998
Dr. Lee E. Limbird, 1997
Dr. Ian Creese, 1996
Dr. Michael Moskowitz, 1995
Dr. Perry Molinoff, 1994